World Asset Management Inc bought a new position in shares of Exact Sciences Corporation (NASDAQ:EXAS) in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,340 shares of the medical research company’s stock, valued at approximately $205,000. World Asset Management Inc owned approximately 3,624.82% of Exact Sciences Corporation as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also bought and sold shares of the company. State of Wisconsin Investment Board acquired a new stake in Exact Sciences Corporation during the 2nd quarter worth approximately $3,006,000. Victory Capital Management Inc. acquired a new stake in Exact Sciences Corporation during the 2nd quarter worth approximately $29,450,000. Eagle Asset Management Inc. increased its position in Exact Sciences Corporation by 19.6% during the 2nd quarter. Eagle Asset Management Inc. now owns 1,857,185 shares of the medical research company’s stock worth $65,688,000 after purchasing an additional 304,598 shares in the last quarter. Federated Investors Inc. PA increased its position in Exact Sciences Corporation by 53.3% during the 2nd quarter. Federated Investors Inc. PA now owns 34,553 shares of the medical research company’s stock worth $1,222,000 after purchasing an additional 12,018 shares in the last quarter. Finally, Bank of Nova Scotia acquired a new stake in Exact Sciences Corporation during the 2nd quarter worth approximately $1,482,000. 85.36% of the stock is owned by hedge funds and other institutional investors.

A number of research firms recently issued reports on EXAS. Zacks Investment Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “hold” rating in a research report on Thursday, November 2nd. BTIG Research downgraded shares of Exact Sciences Corporation from a “buy” rating to a “neutral” rating in a research report on Wednesday, November 1st. Bank of America Corporation increased their target price on shares of Exact Sciences Corporation from $56.00 to $58.00 and gave the stock a “buy” rating in a research report on Tuesday, October 31st. Canaccord Genuity raised shares of Exact Sciences Corporation to a “buy” rating and set a $60.00 target price for the company in a research report on Tuesday, October 31st. Finally, Robert W. Baird increased their target price on shares of Exact Sciences Corporation from $49.00 to $56.00 and gave the stock an “outperform” rating in a research report on Tuesday, October 31st. Seven analysts have rated the stock with a hold rating, nine have issued a buy rating and one has issued a strong buy rating to the company. The company presently has an average rating of “Buy” and a consensus price target of $49.71.

In other Exact Sciences Corporation news, insider Graham Peter Lidgard sold 75,683 shares of the stock in a transaction on Tuesday, September 5th. The stock was sold at an average price of $40.81, for a total value of $3,088,623.23. Following the sale, the insider now directly owns 308,377 shares of the company’s stock, valued at $12,584,865.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Thomas D. Carey bought 2,500 shares of the company’s stock in a transaction on Thursday, August 17th. The stock was bought at an average cost of $37.71 per share, for a total transaction of $94,275.00. Following the completion of the transaction, the director now directly owns 60,858 shares of the company’s stock, valued at $2,294,955.18. The disclosure for this purchase can be found here. Insiders sold 277,373 shares of company stock worth $12,635,570 over the last ninety days. 4.00% of the stock is owned by corporate insiders.

Shares of Exact Sciences Corporation (NASDAQ EXAS) opened at $60.37 on Friday. Exact Sciences Corporation has a 52-week low of $13.05 and a 52-week high of $63.60. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.34 and a quick ratio of 9.98.

Exact Sciences Corporation (NASDAQ:EXAS) last issued its earnings results on Monday, October 30th. The medical research company reported ($0.23) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.30) by $0.07. Exact Sciences Corporation had a negative return on equity of 30.32% and a negative net margin of 60.71%. The firm had revenue of $72.60 million for the quarter, compared to analyst estimates of $65.03 million. During the same period last year, the company earned ($0.36) earnings per share. The firm’s revenue for the quarter was up 158.4% on a year-over-year basis. equities research analysts anticipate that Exact Sciences Corporation will post -1.14 EPS for the current year.

ILLEGAL ACTIVITY NOTICE: “4,340 Shares in Exact Sciences Corporation (EXAS) Purchased by World Asset Management Inc” was published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and reposted in violation of U.S. & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/4340-shares-in-exact-sciences-corporation-exas-purchased-by-world-asset-management-inc/1698143.html.

Exact Sciences Corporation Company Profile

Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA) screening test, which utilizes a multi-target approach to detect deoxyribonucleic acid (DNA) and hemoglobin biomarkers associated with colorectal cancer and pre-cancer.

Want to see what other hedge funds are holding EXAS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Exact Sciences Corporation (NASDAQ:EXAS).

Institutional Ownership by Quarter for Exact Sciences Corporation (NASDAQ:EXAS)

Receive News & Ratings for Exact Sciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exact Sciences Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.